Skip to main content
In stock|Targeted Therapy

Afatinib

Oncology TypeSolid Tumour
Drug Class / MechanismEGFR / HER2 Tyrosine Kinase Inhibitor
No Image
Description

Afatinib is classified as an EGFR / HER2 Tyrosine Kinase Inhibitor, sourced for use within our Targeted Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryTargeted Therapy
Oncology TypeSolid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3